1
|
Hernández-Rubio L, Asensio-Asensio M, Tortosa-Conesa D, Alfaro-Sáez A, García-Escrivá A, Díaz-Román M, Montoya J, Méndez-Miralles MA, Bertol-Alegre V, Castro-Vilanova MD, Galiano ML, Blanco-Cantó ME, López-González F. [Alzemon: a prospective follow-up study of eslicarbazepine acetate monotherapy in patients with newly diagnosed epilepsy]. Rev Neurol 2021; 72:263-268. [PMID: 33851715 DOI: 10.33588/rn.7208.2020593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
INTRODUCTION Eslicarbazepine acetate is a novel sodium channel blocker for use in the treatment of focal onset seizures. Prospective studies on its effectiveness in monotherapy in patients with newly diagnosed partial epilepsy in routine clinical practice are scarce. AIM To evaluate the effectiveness of eslicarbazepine as initial monotherapy in patients with newly diagnosed partial epilepsy in routine clinical practice. PATIENTS AND METHODS A prospective, multicentre, post-authorisation study. Patients with newly diagnosed partial epilepsy aged 18 years or older without previous treatment were included. The efficacy variables were: percentage of seizure-free patients, responders and reduction in monthly frequency of seizures. The safety variables analyse the 12-month retention rate and the occurrence of adverse effects. RESULTS Fifty-three patients were included. The retention rate was 77.4%. At the end of the observation period, 83% of patients were seizure-free and 92.5% had reduced their baseline frequency by 50% or more. In addition, 68% of the patients reported some adverse effect and 7.5% of them dropped out of the study for this reason. The effectiveness analysis of the subgroup of patients aged 65 years or more showed no differences with respect to the overall population. CONCLUSION Eslicarbazepine monotherapy in patients with newly diagnosed partial epilepsy, both in the general population and in the population over 65 years old, is effective and safe in routine clinical practice.
Collapse
Affiliation(s)
| | | | | | - A Alfaro-Sáez
- Hospital Vega Baja, 03314 Orihuela, España.,Universidad Miguel Hernández, Elche, España
| | | | - M Díaz-Román
- Hospital Lluís Alcanyís de Xàtiva, Xàtiva, España
| | - J Montoya
- Hospital General Universitario de Valencia, Valencia, España
| | | | - V Bertol-Alegre
- HUMS. Hospital Universitario Miguel Servet, 50009 Zaragoza, España
| | | | - M L Galiano
- Hospital Universitario Gregorio Marañón, Madrid, España
| | | | | |
Collapse
|
2
|
Villanueva V, Bermejo P, Montoya J, Massot-Tarrús A, Galiano ML, Toledo M, Rodriguez-Uranga JJ, Bertol V, Mauri JÁ, Poza JJ, Bonet M, Castro-Vilanova MD, Ruiz-Giménez J, López-González FJ, Rodríguez-Osorio X, Tortosa-Conesa D, Ojeda J, Giner P, Garcés M, Alvarez BM, Quiroga-Subirana P, Esteve P, Baiges JJ, Hampel K. MONOZEB: Long-term observational study of eslicarbazepine acetate monotherapy. Epilepsy Behav 2019; 97:51-59. [PMID: 31181429 DOI: 10.1016/j.yebeh.2019.05.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 04/26/2019] [Accepted: 05/08/2019] [Indexed: 10/26/2022]
Abstract
AIM The aim of the study was to evaluate the effectiveness and tolerability of eslicarbazepine acetate (ESL) when used as monotherapy for 1 year or more in routine clinical use in patients with focal seizures in epilepsy clinics in Spain. METHODS This is a retrospective, observational, noninterventional study. Eligible patients were aged ≥18 years, had focal seizures, and started on ESL ≥1 year before database closure. Primary endpoint was the following: proportion seizure-free for ≥6 months at 1 and 2 years. Secondary endpoints included retention on ESL monotherapy at 1 and 2 years, seizure frequency change, seizure worsening, and side effects. Other analyses included seizure freedom from baseline to 1 and 2 years and outcomes in special populations. RESULTS Four hundred thirty-five patients were included (127 on first-line monotherapy and 308 converting to ESL monotherapy): median daily dose was 800 mg at all time points; 63.2% were seizure-free at 1 year, 65.1% at 2 years, and 50.3% for the entire follow-up. Mean duration of ESL monotherapy was 66.7 months; retention was 88.0% at 1 year and 81.9% at 2 years. Mean reduction in seizure frequency was 75.5% at last visit. Over the entire follow-up, seizure worsening was seen in 22 patients (5.1%), side effects in 28.0%, considered severe in 1.8%, and leading to discontinuation in 5.7%. Dizziness, hyponatremia (sodium <135 mEq/l), and somnolence were the most frequent side effects. Outcomes in special populations (patients aged ≥65 years and those with psychiatric history or learning difficulty) were consistent with the overall population. CONCLUSIONS Patients with focal seizures taking ESL monotherapy had excellent retention, high seizure-free rates, and good tolerability up to 2 years.
Collapse
Affiliation(s)
| | - Pedro Bermejo
- Hospital Universitario Puerta de Hierro, Madrid, Spain
| | | | | | | | - Manuel Toledo
- Hospital Universitari Vall d'Hebrón, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | - Pau Giner
- Hospital Universitario Doctor Peset, Valencia, Spain
| | | | | | | | | | | | - Kevin Hampel
- Hospital Universitario y Politécnico La Fe, Valencia, Spain
| |
Collapse
|
3
|
Abstract
To identify putative risk factors for levodopa-induced dyskinesias we studied the effect of several clinical variables on the occurrence of dyskinesias in a series of 168 consecutive patients with Parkinson's disease treated for at least 6 months with levodopa. Of these, 108 (64%) developed dyskinesias after a mean duration of levodopa treatment of 51.4 +/- 43.3 months. Patients tended to suffer dyskinesias on the side of the body first affected by Parkinson's disease. The overall probability of developing dyskinesias increased with levodopa treatment duration, about 10% per year during the first 7 years. Univariate and multivariate logistic regression analysis identified the age at onset of Parkinson's disease (OR 0.923; 95% CI 0.883-0.964) and the initial levodopa dose (mean dose of the first 6 months of treatment; OR 1.004; 95% CI 1.002-1.006) as the main independent predictors. Survival curves showed that onset of Parkinson's disease at age 50 years or before (logrank, P < 0.05) and initial levodopa treatment with more than 600 mg/day (logrank, P < 0.05) were associated with a higher risk for the appearance of dyskinesias.
Collapse
Affiliation(s)
- F Grandas
- Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | | |
Collapse
|
4
|
Grandas F, Galiano ML. [Pramipexol: a new dopaminergic agonist for the treatment of Parkinson disease]. Neurologia 1999; 14:224-8. [PMID: 10377723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023] Open
Abstract
Pramipexol is a novel nonergot dopamine agonist which has high selectivity for intereacting with dopamine D2 receptors (especially with D3 receptor subtype). It has been effective in early Parkinson's disease as monotherapy and as adjunctive therapy with L-dopa in advanced stages of the disease. Clinical improvement can be observed after 3 or 4 weeks of treatment. The adverse events profile of pramipexol is similar, in general, to that of other dopamine receptor agonists, although it can be foreseen that pramipexol should not induce side effects related to the ergot chemical structure such as eritromelalgia, distal vasospasm, retroperitoneal fibrosis or pleural effusions. Nevertheless, the potential advantages of this promising dopamine agonist should be tested in well-designed prospective comparative studies with other available ergot and nonergot dopamine agonists.
Collapse
Affiliation(s)
- F Grandas
- Servicio de Neurología, Hospital General Universitario Gregorio Marañón
| | | |
Collapse
|